MARKETS SPECTATOR: Novogen's risk and reward

Risk appetite is alive and well for Novogen investors if the drug maker's successful share sale is anything to go by.

Who says Australians aren’t risk takers? Venture capitalists and the entrepreneurs often bemoan the risk appetite local banks and investors have for innovative ideas. Anti-cancer drug developer Novogen is bucking that perception. It is seeking to raise as much as $6.12 million after earlier this month successfully selling $2.5 million of shares to fund managers.


SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

Related Articles